Tetyana Nehrych, Тетяна Негрич, T Nehrych, Т Негрич
Tetyana Nehrych, Тетяна Негрич, T Nehrych, Т Негрич
Підтверджена електронна адреса в meduniv.lviv.ua - Домашня сторінка
НазваПосиланняРік
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ...
New England Journal of Medicine 367 (12), 1098-1107, 2012
10922012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ...
New England Journal of Medicine 367 (12), 1087-1097, 2012
8632012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ...
The Lancet 380 (9856), 1819-1828, 2012
6872012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ...
The lancet 380 (9856), 1829-1839, 2012
6822012
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
G Giovannoni, G Comi, S Cook, K Rammohan, P Rieckmann, ...
New England Journal of Medicine 362 (5), 416-426, 2010
5322010
Ocrelizumab versus placebo in primary progressive multiple sclerosis
X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ...
New England Journal of Medicine 376 (3), 209-220, 2017
4432017
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ...
The Lancet Neurology 8 (10), 889-897, 2009
4132009
Placebo-controlled trial of oral laquinimod for multiple sclerosis
G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, MA Rocca, M Filippi
New England Journal of Medicine 366 (11), 1000-1009, 2012
3312012
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
C Confavreux, P O'Connor, G Comi, MS Freedman, AE Miller, TP Olsson, ...
The Lancet Neurology 13 (3), 247-256, 2014
3072014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
R Gold, G Giovannoni, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
The Lancet 381 (9884), 2167-2175, 2013
2592013
Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis
O Khan, P Rieckmann, A Boyko, K Selmaj, R Zivadinov, ...
Annals of neurology 73 (6), 705-713, 2013
1732013
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
F Barkhof, HE Hulst, J Drulović, BMJ Uitdehaag, K Matsuda, R Landin
Neurology 74 (13), 1033-1040, 2010
1102010
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
M Filippi, MA Rocca, E Pagani, N De Stefano, D Jeffery, L Kappos, ...
J Neurol Neurosurg Psychiatry 85 (8), 851-858, 2014
932014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
The Lancet Neurology 13 (5), 472-481, 2014
842014
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
652017
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
562017
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ...
Neurology 84 (11), 1145-1152, 2015
382015
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
C Sampaio, J Bronzova, RA Hauser, AE Lang, O Rascol, SV van de Witte, ...
Movement disorders 26 (8), 1464-1476, 2011
352011
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
G Giovannoni, JA Cohen, AJ Coles, HP Hartung, E Havrdova, KW Selmaj, ...
Neurology 87 (19), 1985-1992, 2016
282016
How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
F Fazekas, O Bajenaru, T Berger, T Hojs Fabjan, A Horvat Ledinek, ...
Frontiers in neurology 4, 10, 2013
222013
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20